Gabelli & Co Investment Advisers’s Oaktree Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A ordinary share OACB.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-12,975
Closed -$14K 548
2021
Q4
$14K Hold
12,975
﹤0.01% 464
2021
Q3
$12K Hold
12,975
﹤0.01% 471
2021
Q2
$16K Hold
12,975
﹤0.01% 440
2021
Q1
$16K Hold
12,975
﹤0.01% 409
2020
Q4
$25K Buy
+12,975
New +$18.3K ﹤0.01% 321

Other funds holding OACB.WS

Gabelli & Co Investment Advisers's OACB.WS Position: Q1 2022 in Review

Gabelli & Co Investment Advisers sold out of Oaktree Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A ordinary share (OACB.WS) in Q1 2022, closing a stake of 12,975 shares — an estimated $14K sold.

Gabelli & Co Investment Advisers first reported a position in OACB.WS in Q4 2020 and held it in 5 quarters. The position peaked at $25K in Q4 2020. 30 funds tracked by Wall St. Rank hold OACB.WS as of Q1 2022.

  • Gabelli & Co Investment Advisers reported no remaining Oaktree Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A ordinary share position as of Q1 2022 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 12,975 Oaktree Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A ordinary share shares in Q1 2022, an estimated $14K.
  • Gabelli & Co Investment Advisers first reported a position in Oaktree Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A ordinary share in Q4 2020 and held it in 5 quarters.
  • Gabelli & Co Investment Advisers's Oaktree Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A ordinary share position peaked at $25K in Q4 2020.
  • 30 funds tracked by Wall St. Rank held Oaktree Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A ordinary share as of Q1 2022.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2022, filed 13 May 2022.